Manish Zinzuvadia
Psychiatry · New York, NYNPI 1063726966
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,030,237 of the $1,256,023 with a category attached, or 82.0%. 19 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 25.4% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,722 payments — averaging $729.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$319K
- Alkermes, Inc.$295K
- Otsuka America Pharmaceutical, Inc.$197K
- E.r. Squibb & Sons, L.L.C.$159K
- Neurocrine Biosciences, Inc.$142K
- AbbVie$56K
- plus $87K from 13 others
Across 4 payments — averaging $5312.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$21K
What the payments were for
- Consulting fees$73,8806%
- Speaking & faculty fees$1,030,23782%
- Travel & lodging$100,9268%
- Food & beverage$50,8794%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 344 | $318,602 |
| Alkermes, Inc. | 411 | $294,969 |
| Otsuka America Pharmaceutical, Inc. | 211 | $197,237 |
| E.r. Squibb & Sons, L.L.C. | 158 | $159,321 |
| Neurocrine Biosciences, Inc. | 167 | $142,112 |
| AbbVie(2 entities) | 151 | $56,461 |
| Axsome Therapeutics, Inc. | 58 | $46,143 |
| Luye Pharma (USA) Ltd. | 15 | $15,323 |
| Idorsia Pharmaceuticals US Inc | 5 | $7,135 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $6,987 |
| Johnson & Johnson | 16 | $5,747 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $2,259 |
| Sunovion Pharmaceuticals Inc. | 78 | $1,861 |
| Lundbeck LLC | 64 | $1,094 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $634 |
| Shire North American Group Inc | 2 | $48 |
| Corium, LLC | 2 | $45 |
| Bausch Health US, LLC | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$815,721
- LYBALVI$270,868
- ARISTADA INITIO$186,861
- UZEDY$164,865
- INGREZZA$140,056
- COBENFY$138,253
- REXULTI$137,165
- AUSTEDO$97,748
- ABILIFY MAINTENA$60,060
- VRAYLAR$53,394
- Austedo XR$50,757
- ABILIFY ASIMTUFII$50,388
- Auvelity$45,071
- ERZOFRI EXTENDED-RELEASE$15,266
- QUVIVIQ$7,088
- TRINTELLIX$6,477
- SPRAVATO$5,538
- CAPLYTA$415
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
How this compares
$1,256,023 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UzedyRisperidone | 320 | $1,092,958 |
| Abilify AsimtufiiAripiprazole | 73 | $411,836 |
| AristadaAripiprazole Lauroxil | 110 | $339,984 |
| Austedo XrDeutetrabenazine | 39 | $317,398 |
| IngrezzaValbenazine Tosylate | 23 | $198,816 |
| RexultiBrexpiprazole | 118 | $181,033 |
| VraylarCariprazine Hcl | 93 | $143,541 |
| Invega SustennaPaliperidone Palmitate | 45 | $138,233 |
| Olanzapine | 639 | $72,769 |
| Quetiapine Fumarate | 485 | $54,370 |
| Risperidone | 571 | $50,761 |
| TrintellixVortioxetine Hydrobromide | 93 | $48,278 |
| LybalviOlanzapine/Samidorphan Malate | 29 | $48,058 |
| Paliperidone ErPaliperidone | 86 | $40,994 |
| Divalproex Sodium | 274 | $39,205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Uzedy, Austedo Xr | $318,602 | $1,410,356359 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $197,237 | $592,869191 claims |
| Alkermes, Inc.Aristada, Lybalvi | $294,969 | $388,042139 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $142,112 | $198,81623 claims |
| AbbVieVraylar | $56,461 | $143,54193 claims |
| Johnson & JohnsonInvega Sustenna | $5,747 | $138,23345 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $6,987 | $48,27893 claims |
| E.r. Squibb & Sons, L.L.C.Cobenfy | $159,321 | $25,40513 claims |
| Axsome Therapeutics, Inc.Sunosi | $46,143 | $11,14412 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $7,135 | $9,39618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in New York
- Jianping ChenNew York$1.2M
- Ulla Kristina LaaksoNew York$890K
- Kerry SulkowiczNew York$435K
- Ralph AquilaNew York$143K
- Daniel KarlinNew York$101K
- David StraussNew York$95K
- Anissa Abi-DarghamNew York$94K
- Robin McGarryNew York$69K
- Nicole AllenNew York$63K
- Leslie CitromePomona$5.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.